NASDAQ · Biotechnology

Aptose Biosciences Inc. (APTO) Stock

$1.71 +100.00% NASDAQ: APTO Healthcare

Aptose Biosciences Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to discovering and advancing personalized therapeutic solutions to address critical unmet medical needs within the field of oncology, primarily focusing on the United States market.

Valuation

MetricValue
Price$1.71
Market Cap$4.36M
P/E Ratio-0.16
P/B Ratio-0.13
P/S Ratio0.00
EPS (TTM)$-10.41
52-Week High$43.19
52-Week Low$1.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-23.18%
ROA51.69%
ROCE0.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio0.55

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-65.0M$-43.0M$-52.0M$0$0
Net Profit$-65.0M$-42.0M$-51.0M$-25.0M$0
EPS$-34.56$-22.12$-27.08$-18.94$-10.41
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$83.0M$51.0M$13.0M$10.0M$10.0M
Total Liabilities$8.0M$13.0M$16.0M$15.0M$37.0M
Cash$39.0M$37.0M$9.0M$6.0M$1.0M
Borrowings$1.0M$1.0M$1.0M$11.0M$0

Latest News

Niki BioSolutions Enters into Strategic Agreement to Provide APOE Testing Services for Progressive Medical Research (PMR) GlobeNewswire · Jul 23, 2026 Aptorum Group Provides Update on DiamiR Biosciences Merger GlobeNewswire · Jul 16, 2026 Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer’s Association International Conference GlobeNewswire · Jul 8, 2026 Aptorum's Merger Target DiamiR Begins Alzheimer's Biomarker Study With AlzLabs MT Newswires · Jun 22, 2026 Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer’s Disease Biomarkers GlobeNewswire · Jun 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-43.0M$-32.0M$-45.0M$-36.0M$0
Investing Cash Flow$-35.0M$30.0M$10.0M$0$0
Financing Cash Flow$0$0$0$0$19.0M
Net Cash Flow$-78.0M$-2.0M$-28.0M$-3.0M$-3.0M
Free Cash Flow$-44.0M$-32.0M$-45.0M$-36.0M$0

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-2.33
FCF Yield0.00%
Quick Ratio0.55
Interest Coverage-8.64
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AFMDAffimed N.V. $0.18 +0.00% -0.02 $2.98M 0.00%
ARAVAravive, Inc. $0.04 -13.39% -0.02 $2.95M 0.00%
BCELAtreca, Inc. $0.09 -1.32% -0.04 $3.57M 0.00%
GMDAGamida Cell Ltd. $0.03 +0.00% -0.08 $4.34M 0.00%
GRTSGritstone bio, Inc. $0.03 -31.78% -0.03 $3.80M 0.00%

About Aptose Biosciences Inc.

Aptose Biosciences Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to discovering and advancing personalized therapeutic solutions to address critical unmet medical needs within the field of oncology, primarily focusing on the United States market. Its active clinical pipeline features several promising candidates. APTO-253 is currently undergoing Phase 1a/b clinical evaluation for patients battling relapsed or treatment-resistant blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS). Another compound, HM43239, is progressing through Phase 1/2 clinical trials, specifically targeting individuals with relapsed or refractory AML. Furthermore, luxeptinib is in Phase 1a/b clinical testing, designed to treat patients suffering from recurring or treatment-resistant B-cell malignancies—such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas—as well as AML and HR MDS. Aptose also has APL-581 under development, a program centered on a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor. The company has established strategic agreements with CrystalGenomics, Inc. and OHM Oncology. Incorporated in 1986, Aptose Biosciences Inc. previously operated as Lorus Therapeutics Inc. before adopting its current name in August 2014. Its corporate headquarters are located in Toronto, Canada.

Aptose Biosciences Inc. is headquartered in CA.

Aptose Biosciences Inc. (APTO) stock trades at $1.71 with a market capitalization of $4.36M. The stock is valued at a price-to-earnings (P/E) ratio of -0.16, price-to-book of -0.13, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.10 and $43.19, and currently trades 96.0% below its 52-week high.

On profitability, Aptose Biosciences Inc. generates a return on equity (ROE) of -23.18%, return on capital employed of 0.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.aptose.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides